Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

NCT03785873 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Nivolumab
DRUG: Nanoliposomal-Irinotecan
DRUG: 5-Fluorouracil
DRUG: Leucovorin

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]
[object Object]